{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:28:58Z","timestamp":1790710138723,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>There is always a lack of effective treatment for highly active refractory generalized myasthenia gravis (GMG). Recently, telitacicept combined with efgartigimod significantly reduces circulating B cells, plasma cells, and immunoglobulin G, which brings promising therapeutic strategies. We report a case of a 37-year-old female patient with refractory GMG, whose condition got significant improvement and control with this latest treatment after multiple unsuccessful therapies of immunosuppressants. The new combination deserves further attention in the therapeutic application of myasthenia gravis.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1400459","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:24:44Z","timestamp":1715315084000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod"],"prefix":"10.3389","volume":"15","author":[{"given":"Chaoyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangtao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol 2022"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol 2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2207739","article-title":"Conventional and emerging treatments and controversies in myasthenia gravis","volume":"23","author":"Evoli","year":"2023","journal-title":"Expert Rev Neurother. 2023"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.4520","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (adapt): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/annrheumdis-2023-eular.4616","article-title":"Pos1149 comparison of the efficacy and safety of telitacicept versus belimumab in patients with systemic lupus erythematosus in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting","volume":"82","author":"Jin","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.ejps.2021.105704","article-title":"Pharmacokinetics analysis based on target-mediated drug distribution for rc18, a novel blys\/april fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis","volume":"159","author":"Yao","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a blys\/april dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol. 2021"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330519","article-title":"Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis","volume":"94","author":"Uzawa","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad153","article-title":"The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (farad)","volume":"146","author":"Allen","year":"2023","journal-title":"Brain (London Engl 1878)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-cd20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40478-022-01454-0","article-title":"Reemergence of pathogenic, autoantibody-producing b cell clones in myasthenia gravis following b cell depletion therapy","volume":"10","author":"Fichtner","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies directed against b-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs 2019"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/mus.v56.2","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"B16","doi-asserted-by":"publisher","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"115872","DOI":"10.1016\/j.bcp.2023.115872","article-title":"Myasthenia gravis: molecular mechanisms and promising therapeutic strategies","volume":"218","author":"Chen","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.06.014","article-title":"Baff signaling in health and disease","volume":"71","author":"Schweighoffer","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","article-title":"Keeping up with the stress of antibody production: baff and april maintain memory plasma cells","volume":"71","author":"Cornelis","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"475970702","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bcp.12908","article-title":"Pharmacokinetics, pharmacodynamics, short term efficacy and safety of rct-18, a novel blys\/april fusion protein, in patients with rheumatoid arthritis","volume":"82","author":"Chen","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1321058","article-title":"Case report: recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod","volume":"15","author":"Watanabe","year":"2024","journal-title":"Front Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-020-00989-1","article-title":"Drug dosing in patients undergoing therapeutic plasma exchange","volume":"34","author":"Mahmoud","year":"2021","journal-title":"Neurocrit Care"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1400459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:24:47Z","timestamp":1715315087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1400459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2024.1400459"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1400459","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"article-number":"1400459"}}